Literature DB >> 27697808

A new urticarial rash, diarrhoea and refractory hypotension in a man with a history of migraines.

Lucy Lamb1, David Lowe2.   

Abstract

We present the case of a man with a history of migraines treated with propanolol, referred with a rash, diarrhoea, vomiting and hypotension. Our case highlights how prior beta-blocker use may prolong anaphylaxis and cause refractory hypotension. © Royal College of Physicians 2016. All rights reserved.

Entities:  

Keywords:  Beta-blockers; prolonged anaphylaxis; refractory hypotension; tryptase

Mesh：

Substances：

Year:  2016        PMID： 27697808      PMCID： PMC6297297          DOI： 10.7861/clinmedicine.16-5-451

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


  7 in total

Review 1.  Biphasic anaphylactic reactions.

Authors:  Phil Lieberman
Journal:  Ann Allergy Asthma Immunol       Date:  2005-09       Impact factor: 6.347

2.  Emergency department diagnosis and treatment of anaphylaxis: a practice parameter.

Authors:  Ronna L Campbell; James T C Li; Richard A Nicklas; Annie T Sadosty
Journal:  Ann Allergy Asthma Immunol       Date:  2014-12       Impact factor: 6.347

3.  Tryptase serum level as a possible indicator of scombroid syndrome.

Authors:  Giorgio Ricci; Massimo Zannoni; Davide Cigolini; Costantino Caroselli; Rosalia Codogni; Beatrice Caruso; Elisa Bonello; Giampaolo P Rocca
Journal:  Clin Toxicol (Phila)       Date:  2010-03       Impact factor: 4.467

4.  Use of beta-blockers during immunotherapy for Hymenoptera venom allergy.

Authors:  Ulrich R Müller; Gabrielle Haeberli
Journal:  J Allergy Clin Immunol       Date:  2005-03       Impact factor: 10.793

5.  Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with both beta-blocker exposure and cardiovascular disorders.

Authors:  D M Lang; M B Alpern; P F Visintainer; S T Smith
Journal:  Arch Intern Med       Date:  1993-09-13

Review 6.  Beta-blocker therapy and the risk of anaphylaxis.

Authors:  J H Toogood
Journal:  CMAJ       Date:  1987-05-01       Impact factor: 8.262

Review 7.  Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.

Authors:  Susan L Limb; Peter R Starke; Charles E Lee; Badrul A Chowdhury
Journal:  J Allergy Clin Immunol       Date:  2007-10-22       Impact factor: 10.793
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.